Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Core Points - Alkermes plc held a conference call to discuss the results of the Vibrance-1 Phase II study of alixorexton in patients with narcolepsy type 1 [2] Group 1 - The conference call featured key executives including the CEO Richard Pops and Chief Medical Officer Dr. Craig Hopkinson, along with the lead investigator Professor Giuseppe Plazzi [2] - A press release and slide presentation related to the study results were made available on the Investors section of alkermes.com [2]